Iptacopan
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 180 publications
Complement targeting in autoimmune diseases.
Journal: Current opinion in hematology
Published: September 08, 2026
Global research landscape of C3 glomerulopathy: A bibliometric analysis.
Journal: Clinical nephrology
Published: August 14, 2026
Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy.
Journal: Kidney international reports
Published: August 09, 2026
Methodological pitfalls in indirect treatment comparisons: insights from a recent systematic review and analysis for C3 glomerulopathy.
Journal: Journal of comparative effectiveness research
Published: August 06, 2026
Sibeprenlimab (Voyxact) for primary immunoglobulin A nephropathy.
Journal: The Medical letter on drugs and therapeutics
Published: July 24, 2026
Real-World Outcomes of Iptacopan in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Journal: Kidney international reports
Published: July 24, 2026
Long-term efficacy and safety for the complement factor B inhibitor iptacopan in IgA nephropathy.
Journal: Kidney international
Published: July 17, 2026
Complement System Inhibitors in Nephrology: A Comprehensive Review.
Journal: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
Published: July 09, 2026
Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.
Journal: American journal of hematology
Published: July 09, 2026
IgA nephropathy: evolving pathogenic concepts and emerging targeted therapies.
Journal: Human immunology
Published: July 07, 2026
Pivotal Clinical Trials in C3 Glomerulopathy: answers and remaining uncertainties.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: July 03, 2026
Last Updated: 11/08/2026